A Novel Strategy for Designing Dual-Target Inhibitors of KU86 and XRCC4

This is the first time that we reported about dual target inhibitors of KU86 and XRCC4. XRCC4 was well known as the downstream of KU86-DNA complex. They both play an important role in the DNA double-strain breaks (DSBs) repair system subpathway, non-homologous end joining (NHEJ).In this study, The p...

Full description

Saved in:
Bibliographic Details
Published in2009 2nd International Conference on Biomedical Engineering and Informatics pp. 1 - 4
Main Authors Chien-Yu Chen, Fuu-Jen Tsai, Jing-Gung Chung, Chang-Hai Tsai, Yuan-Man Hsu, Hung-Jin Huang, Tin-Yun Ho, Yea-Huey Chang, Da-Tian Bau, Ming-Hsui Tsai, Chen, C.Y.-C.
Format Conference Proceeding
LanguageEnglish
Published IEEE 01.10.2009
Subjects
Asia
Bioinformatics
Cancer
DNA
Drugs
Hospitals
Humans
Inhibitors
Proteins
Online AccessGet full text

Cover

More Information
Summary:This is the first time that we reported about dual target inhibitors of KU86 and XRCC4. XRCC4 was well known as the downstream of KU86-DNA complex. They both play an important role in the DNA double-strain breaks (DSBs) repair system subpathway, non-homologous end joining (NHEJ).In this study, The protocol of docking analysis was applied to find the specific compounds, which had highest affinities to KU86 and XRCC4, from our database. The docking results were analyzed by cross validation. From the results above, myricetin and xanthone series had quietly the same core structure. The different shapes of binding sites from the two proteins might be the major factor to different affinities from these three potent dual-target inhibitors. Our work provides a new strategy for developing dual-target anticancer drug, and may contribute to clinical anticancer drug discovery and application.
ISBN:9781424441327
1424441323
ISSN:1948-2914
1948-2922
DOI:10.1109/BMEI.2009.5302325